Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 14/20 | 0.51 |
| ▸ | SCTR | P47872 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31740815 | 0.96 | GLP1R (0.56) | GLP1RSCTRGCGR | |
| SCHEMBL31741239 | 0.94 | GLP1R (0.55) | GLP1RSCTRGCGR | |
| SCHEMBL2465543 | 0.92 | GLP1R (0.50) | GLP1RSCTROPRM1OPRD1OPRL1 | |
| SCHEMBL29860168 | 0.92 | OPRM1 (0.57) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL30635331 | 0.92 | GLP1R (0.60) | GLP1RSCTRGCGR | |
| SCHEMBL29375282 | 0.90 | GLP1R (0.56) | GLP1RSCTR | |
| SCHEMBL677186 | 0.90 | GLP1R (0.45) | GLP1RSCTROPRM1OPRD1OPRL1 | |
| SCHEMBL29616372 | 0.90 | GLP1R (0.56) | GLP1RSCTROPRM1OPRD1OPRK1 | |
| SCHEMBL29376195 | 0.90 | GLP1R (0.48) | GLP1RSCTR | |
| SCHEMBL31253154 | 0.90 | GLP1R (0.45) | GLP1RSCTROPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | GLP1R 1/4885SCTR 22/4885OPRM1 4009/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | GLP1R 1/4885SCTR 22/4885OPRM1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.